ANAHEIM, CA, Might 17, 2022 (WORLD NEWSWIRE)– through NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Business”), a designer and provider of ingenious treatment programs for substance abuse and associated disorders, today offered a business update for the first quarter ended March 31, 2022 and reported on current business advancements.
Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “We are happy to report development on our upcoming first-in- human clinical trial of BICX104, an implantable naturally degradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being established under BioCorRx Pharmaceuticals, Inc., the Business’s controlled R&D subsidiary.”
” Last month, we revealed that we have actually started the recruiting and registrationprocess for the clinical trial This was a significant turning point as it marks the next stage of advancement for BICX104. The BICX104 clinical research study is a Stage 1, open-label, single-center research study in 2 parallel groups of randomized healthy volunteers to examine the pharmacokinetics and security of BICX104 implantable subcutaneous naltrexone pellets and the marketed when a month intramuscular depot naltrexone injection. We are in the hiring stage and look forward to offering development updates as they appear.”
” In addition, we saw an boost in profits in the first quarter of 2022 due to the increased number of patients dealt with at certified centers. In addition, we were happy to see that subscription/program costs likewise increased for the first quarter of 2022 due to more consumers registering for our UnCraveRx ™ Weight Reduction Management Program.
At the very same time, we continue to thoroughly handle expenditures and decreased operating costs by almost 30%.”
BICX104 is being established in cooperation with the National Institute on Substance Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002,
“ Advancement of Medications to Prevent and Deal With Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)” The Business has an active Investigational New Drug (IND) status, and the FDA has actually considered the 505( b)( 2) shortened path appropriate, too the chance to seek ultimate dual indicator on the item for OUD and Alcohol Use Disorder (AUD).
A copy of the Business’s yearly report on Kind 10-Q for the first quarter ended March 31, 2022 has actually been submitted with the Securities and Exchange Commission and published on the Business’s site at https://ir.biocorrx.com/
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment options business using a special approach to the treatment of substance use and other associateddisorders Beat Addiction Recovery is a substance use disorder recovery program that normally consists of BioCorRx’s exclusive Cognitive Behavioral Therapy (CBT) modules along with peer assistance through mobile app along with medication recommended by an independent treating doctor under their discretion. The UnCraveRx ® Weight Reduction Program is likewise a medication assisted weight-loss program that consists of gain access to to concierge on- need health experts: nutritional experts, physical fitness professionals and individual assistance from behavioral professionals; please go to www.uncraverx.com for more information on UnCraveRx ®. The Business likewise manages BioCorRx Pharmaceuticals, a clinical phase drug advancement subsidiary presently looking for FDA approval for BICX104, an implantable naltrexone pelletfor treatment of alcohol and opioid use disorders For more information on BICX and its subsidiary pipeline, please go to www.BioCorRx com
Safe Harbor Declaration
The information in this release consists of positive declarations. These positive declarations usually are determined by the words “think,” “job,” “price quote,” “ended up being,” “plan,” “will,” and comparable expressions. These positive declarations include understood and unidentified. dangers along with unpredictabilities. Although the Business thinks that its expectations are based on sensible presumptions, the real outcomes that the Business might accomplish might vary materially from any positive declarations, which show the viewpoints of the management of the Business just as of the date hereof.
BioCorRx Inc.
.
financiers @
BioCorRx
.
com
. 714-462-4880
. Financier Relations:
. Crescendo Communications, LLC
. 212- 671-1020 x304
. bicx@crescendo-ir.com
Media Contact
.
PhillComm Global
.BioCorRx
@PhillComm.
Worldwide
.
704-942-1557
.
.